HF-POLARIS

zenagamtide | effects on heart failure outcomes in people with obesity

National Data Package

National Leader:

Mpiko Ntsekhe

novo nordisk®

Participant overview

Participant overview	Overall recruitment target	Participants screened	Participants randomised	Screen failure rate*	Off treatment
	N	N	N	%	N
South Africa	175	26	3	78	2
Global	5,610	1,064	438	46	12

**Forecasted*

Participants randomised and recruitment target in South Africa in 2026



Screen failure reasons

Screen failure reasons	South Africa	Global*
	N (%)	N (%)
NT-proBNP (I7)	6 (43)	153 (38)
HF decompensation/ eGFR/UACR (I8)	3 (21)	104 (26)
Investigator discretion (E31)	1 (7)	22 (5)
HbA_{1c} >10% (E12)	1 (7)	12 (3)
LVEF (I5)	0 (0)	12 (3)
Diabetic retinopathy (E10)	0 (0)	10 (3)
ICF process (I1)	0 (0)	8 (2)
BMI (I3)	0 (0)	8 (2)
Malignancy history (E22)	0 (0)	7 (2)
Insulin therapy (E11)	1 (7)	6 (2)
Other	2 (14)	64 (16)

**Globally, 34 participants (13%) failed due to more than one eligibility criteria*
BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA_1C, glycated haemoglobin; HF, heart failure; ICF, Informed Consent Form; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal B-type natriuretic peptide.

Site-level data

Planned number of sites: 23

Site*	PI	Participants, N			
		Screened	In screening	Screen failed	Randomised
5305	Hendrik Snyman	6	1	4	1
5306	Muhammed Fulat	8	4	3	1
5308	Fezeka Wulana	2	2	0	0
5311	Zarinah Mohamed	2	0	2	0
5314	Thirumani Govender	3	1	2	0
5315	Dorothea Urbach	4	1	2	1
5320	Douwe De Jong	1	0	1	0

**Only sites that have actively started recruitment are included*

Notes

Notes

What are the challenges you face or anticipate facing concerning:

Recruitment?

Retention?

Collaboration with other stakeholders?

Are there any challenges in other areas that you'd like to address in your action plan?

What actions or initiatives can you implement to help resolve these issues?